A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy

Trial Profile

A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2017

At a glance

  • Drugs Rifaximin (Primary) ; Lactulose
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 15 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 May 2014 New source identified and integrated (Mayo Clinic; IRB13-000483).
    • 23 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top